RxDoctor Payments DataLook up a doctor →

Steven Musick, DO

Pain Medicine · Chattanooga, TNNPI 1174552822

Payments from drug & device makers

$6,564in general payments, 2019–2025

Across 347 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Ipsen Biopharmaceuticals, Inc$822
  • Radius Health, Inc.$610
  • Amgen$429
  • Johnson & Johnson$385
  • Avanir Pharmaceuticals, Inc.$336
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$6,43398%
  • Education$1312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,564 in reported general payments places this provider in the 65th percentile of 112 pain medicine providers in Tennessee.

See all pain medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$105,541
Medicare patients
331
Services billed
1,960

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate54$37,320
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen854$25,324
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen504$16,908
OxycontinOxycodone Hcl16$13,842
LinzessLinaclotide17$9,822
MovantikNaloxegol Oxalate14$8,917
Oxycodone Hcl403$8,731
BelbucaBuprenorphine Hcl14$8,707
Morphine Sulfate ErMorphine Sulfate290$7,120
Buprenorphine33$6,083
Gabapentin376$5,239
Pregabalin178$2,720
Naloxone Hcl39$2,415
Fentanyl30$2,332
Tramadol Hcl ErTramadol Hcl23$2,195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$281$46,02868 claims
AbbVieLinzess$1,008$9,82217 claims
Redhill Biopharma Inc.Movantik$12$8,91714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 112 pain medicine providers in Tennessee.

Other pain medicine in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →